The recently IPO'd Foundation Medicine ($FMI) has expanded its relationship with Novartis ($NVS), lending out its gene-profiling technology to help the drugmaker develop cancer treatments. Under the deal, Foundation will team up with Novartis to evaluate oncology candidates, develop biological targets and recruit patients for clinical trials, the company said, using the technology behind its FoundationOne diagnostic. Article